Donanemab side effects caregivers should watch for are brain swelling or bleeding called ARIA, plus infusion reactions. Call the care team promptly for headache, confusion, dizziness, nausea, vision changes, difficulty walking, or seizure.
Donanemab-azbt (Kisunla) is an amyloid-targeting infusion for adults with early symptomatic Alzheimer's, meaning mild cognitive impairment or mild dementia with confirmed amyloid pathology. The U.S. FDA approved it on July 2, 2024, according to the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why does ARIA matter so much?
- How common is ARIA?
- Who faces higher risk?
- What warning signs need a fast call?
- How do MRIs and infusions fit in?
- Frequently Asked Questions
Why does ARIA matter so much?
ARIA means amyloid-related imaging abnormalities. ARIA-E is swelling or fluid around the brain, while ARIA-H is tiny bleeds or iron deposits.
Kisunla carries a boxed warning because ARIA can be serious, life-threatening, or fatal. Eli Lilly reports that ARIA is often asymptomatic, so symptoms alone cannot rule it out.
How common is ARIA?
In TRAILBLAZER-ALZ 2, ARIA-E occurred in 24.0% of donanemab patients versus 2.1% on placebo. Symptomatic ARIA-E occurred in about 6.1%, according to an NIH/PMC review of the JAMA trial.
ARIA-H occurred in 31.4% versus 13.6% on placebo. Three deaths in the donanemab group were considered treatment-related after serious ARIA, versus one death in placebo.
Who faces higher risk?
Genetic risk matters. ARIA risk is highest in ApoE ε4 homozygotes, about 55% on donanemab, versus 36% in heterozygotes and 25% in noncarriers.
The label directs ApoE ε4 testing before starting treatment, according to the Drugs.com professional monograph citing the FDA label. Ask whether results change monitoring, dose pauses, or treatment choice.
What warning signs need a fast call?
The Alzheimer's Association advises caregivers to promptly report symptoms that can signal symptomatic ARIA or infusion problems, described on its donanemab page. Do not wait to see whether symptoms fade. Note onset time, new medicines, falls, and recent infusions.
- New or worse headache
- Confusion or thinking change
- Dizziness, nausea, or seizure
- Vision changes or difficulty walking
How do MRIs and infusions fit in?
FDA labeling requires a recent baseline brain MRI plus MRIs before the 2nd, 3rd, 4th, and 7th infusions. The scans detect ARIA early and guide interruption or discontinuation, according to the FDA prescribing information.
Infusion-related reactions occurred in 9% of donanemab patients versus 0.5% on placebo, with 70% happening within the first four infusions. Hypersensitivity including anaphylaxis and angioedema has also occurred, so report rash, swelling, breathing trouble, chills, or fever during or after infusion.
Frequently Asked Questions
Does no headache mean no ARIA?
No. ARIA is often silent on scans, so keep every scheduled MRI even when the person feels well.
What should I bring to an urgent visit?
Bring infusion dates, symptom onset, ApoE result if known, recent MRI dates, and a list of blood thinners and new drugs.
Can treatment continue after ARIA?
Sometimes the team pauses dosing, repeats MRI scans, then decides whether to resume or stop. Follow the prescribed MRI and visit schedule exactly.
You Might Also Like
- Donanemab for Dementia: Benefits, Risks, and Who May Qualify
- The NIA 2026 Dementia Care and Caregiving Summit Report: What the Report Establishes and Leaves Unanswered for Working Dementia Caregivers
- The Ideal Dementia Care Map Discussed by NIA in 2026: What the Report Establishes and Leaves Unanswered for Long-Distance Caregivers





